BioVie Inc.
NCM: BIVILive Quote
About BioVie Inc.
Healthcare
Biotechnology
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
📊 Fundamental Analysis
BioVie Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -80.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.35, BIVI currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $1.06 - $13.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$12.59M
Trailing P/E
--
Forward P/E
-0.31
Beta (5Y)
0.56
52W High
$13.20
52W Low
$1.06
Avg Volume
87K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App